Market Analysis and Price Projections for NDC 0781-2343: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate
Overview of the Drug
The drug with the NDC code 0781-2343 is a combination of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, marketed by Sandoz Inc. It is an oral, extended-release capsule used primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and certain cases of narcolepsy[1][5].
Market Context
Generic Drugs Market
The U.S. generic drugs market, which includes drugs like the one with NDC 0781-2343, is projected to grow significantly. By 2033, the market size is expected to surpass $188.44 billion, growing at a Compound Annual Growth Rate (CAGR) of 3.5% from 2023 to 2033. This growth is driven by factors such as maximizing savings for healthcare systems and patients[4].
Specialty Pharmaceuticals
While the drug in question is a generic, the broader pharmaceutical market is also influenced by specialty pharmaceuticals. These drugs, which treat complex or chronic conditions, are driving a significant portion of the drug price inflation. According to Vizient, Inc., drug price inflation is projected to grow at 3.8% in 2024, with specialty pharmaceuticals contributing to this increase[2].
Price Projections
General Trends
The overall pharmaceutical market is experiencing price increases, particularly driven by specialty drugs. However, generic drugs tend to have more stable pricing due to competition.
Specific Projections
For generic drugs like Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, price increases are generally more modest compared to specialty drugs. Given the competitive nature of the generic drug market, it is unlikely that this drug will see significant price hikes. Instead, prices may remain relatively stable or increase at a rate similar to the overall inflation rate of the generic drugs market, around 3.5% CAGR[4].
Regulatory and Market Dynamics
Regulatory Landscape
The regulatory landscape for pharmaceuticals is evolving, with a focus on innovation and patient-centered care. While these changes primarily affect new drug developments, they can also impact the pricing and availability of existing generic drugs. However, for established generics like NDC 0781-2343, regulatory changes are less likely to cause significant price fluctuations[3].
Supply Chain and Expenditure Management
Managing pharmacy expenditures and strengthening the supply chain are critical due to drug shortages and rising costs. This emphasis can lead to more efficient pricing and distribution strategies for generic drugs, potentially stabilizing or reducing prices[2].
Key Takeaways
- Market Growth: The U.S. generic drugs market is expected to grow, reaching $188.44 billion by 2033.
- Price Stability: Generic drugs, including NDC 0781-2343, are likely to see stable or modest price increases, around 3.5% CAGR.
- Regulatory Impact: Evolving regulatory landscapes may influence pricing but are less likely to significantly impact established generic drugs.
- Supply Chain Management: Efficient supply chain management can help stabilize or reduce prices.
FAQs
Q: What is the primary use of the drug with NDC 0781-2343?
A: The drug is primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and certain cases of narcolepsy.
Q: Who is the manufacturer of this drug?
A: The drug is manufactured by Sandoz Inc.
Q: What is the projected growth rate of the U.S. generic drugs market?
A: The U.S. generic drugs market is projected to grow at a CAGR of 3.5% from 2023 to 2033.
Q: How do specialty pharmaceuticals impact the overall drug price inflation?
A: Specialty pharmaceuticals are driving a significant portion of the drug price inflation, with a projected increase of 4.18% in 2024.
Q: What factors contribute to the stability of generic drug prices?
A: Factors such as competition in the generic drug market and efficient supply chain management contribute to the stability of generic drug prices.
Sources
- FDA.report: NDC 0781-2343 - Amphetamine Sulfate.
- Vizient Inc.: Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals.
- TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
- Biospace: U.S. Generic Drugs Market Size to Surpass USD 188.44 Bn by 2032.
- FindACode: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate.
